Ligand Pharmaceuticals Incorporated

LGND

US53220K5048

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
70.37 ^USD	-0.89%		-2.96%	-1.47%

Apr. 08	Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	CI
Apr. 03	Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	CI

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to S&P 600

September 07, 2021 at 12:00 am EDT

Latest news about Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	Apr. 08	CI
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	Apr. 03	CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	Apr. 02	CI
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	Feb. 27	MT
Transcript : Ligand Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	Feb. 27	CI
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	Feb. 27	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	Feb. 27	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Ligand Pharmaceuticals Incorporated Announces Management Appointments	Feb. 16	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	Jan. 08
Investors lower their expectations	Jan. 08
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication; Shares Jump Premarket	Jan. 08	MT
Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment	Jan. 05	DJ
Ligand Pharma's at-home skin treatment gets FDA approval	Jan. 05	RE
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication	Jan. 05	MT
Ligand Pharma's topical skin drug gets US FDA approval	Jan. 05	RE
U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum	Jan. 05	CI
Ligand Pharmaceuticals Sets 2024 Earnings, Revenue Guidance	Dec. 12	MT
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024	Dec. 12	CI
Transcript : Ligand Pharmaceuticals Incorporated - Analyst/Investor Day	Dec. 12
Ligand Pharmaceuticals Expands Partnership With Palvella Therapeutics to Advance Qtorin	Dec. 01	MT
Tranche Update on Ligand Pharmaceuticals Incorporated's Equity Buyback Plan announced on August 8, 2023.	Nov. 09	CI
Transcript : Ligand Pharmaceuticals Incorporated, Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q3 Revenue $32.9M, vs. Street Est of $27.2M	Nov. 08	MT

Chart Ligand Pharmaceuticals Incorporated

Duration

Period

Chart Ligand Pharmaceuticals Incorporated

More charts

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

70.37 USD

Average target price

116.8 USD

Spread / Average Target

+65.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIGAND PHARMACEUTICALS INCORPORATED	-1.47%	1.26B
NOVO NORDISK A/S	+24.81%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+12.92%	233B
NOVARTIS AG	+5.43%	201B
ROCHE HOLDING AG	-10.02%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals